FDA批准Rybelsus心脏病风险调查;Google在混合经济信号下推出AI视频工具。 FDA approves Rybelsus for heart risk; Google launches AI video tool amid mixed economic signals.

Streamwide 报告称，2025 年上半年收入增长 23.9%，净利润更高，而米高梅国际度假村在出售其俄亥俄州赌场并撤回纽约牌照竞标后，再次引发了人们对 Entain PLC 潜在竞标的猜测，产生了 4.2 亿美元的净收益。 Streamwide reported a 23.9% revenue increase and higher net profit in the first half of 2025, while MGM Resorts International drew renewed speculation about a potential bid for Entain PLC after selling its Ohio casino and withdrawing a New York license bid, generating $420 million in net proceeds. Sobi公司更新了其全年展望,以收入增加和调整了EBITA的利润幅度为理由,并获得美国批准其儿科药物Doptelet。 Sobi upgraded its full-year outlook, citing stronger revenue and adjusted EBITA margins, and received U.S. approval for its pediatric drug Doptelet. 同时,林业发展局批准Novo Nordisk的Rybelsus用于降低心血管风险,Google推出了Veo 3.1,这是一个高级人工智能视频工具,因为市场对混合经济信号和公司活动作出反应。 Meanwhile, the FDA approved Novo Nordisk’s Rybelsus for cardiovascular risk reduction, and Google launched Veo 3.1, an advanced AI video tool, as markets reacted to mixed economic signals and ongoing corporate activity.